0001652935 1 2026-07-31 2026-07-31 0001652935 2 2026-07-31 2026-07-31 0001652935 3 2026-07-31 2026-07-31 0001652935 1 2026-07-31 2026-07-31 0001652935 2 2026-07-31 2026-07-31 0001652935 2026-07-31 2026-07-31 iso4217:USD S-1/A EX-FILING FEES 0001652935 333-299332 true false N/A S-1 Actuate Therapeutics, Inc. true Equity Common stock true 26162500.00 2276.14 true Equity Warrants to be issued to the underwriter true 0.00 0.00 true Equity Common stock underlying warrants to be issued to the underwriter true 1144609.38 99.59 27307109.38 2375.73 0.00 2375.73 0.00 In accordance with Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall be deemed to cover an indeterminate number of additional shares of Common Stock to be offered or issued from stock splits, stock dividends or similar transactions.<br/><br/>The proposed maximum aggregate offering price has been estimated solely to calculate the registration fee in accordance with Rule 457(o) under the Securities Act.<br/> No registration fee required pursuant to Rule 457(g).<br/><br/>We have agreed to issue to the underwriter warrants to purchase shares of common stock representing up to 3.5% of the common stock issued in the offering. The underwriter’s warrants are exercisable at a per share exercise price equal to 125% of the public offering price per share of the common stock offered hereby.<br/><br/> true S-1 333-299332 2026-10-06 2375.73 true Actuate Therapeutics, Inc. S-1 333-299332 2026-10-06 2375.73 The Company previously paid $2,375.73 with respect to common stock included herein based on a maximum aggregate offering price of $34,500,000.00 in connection with its filing of the Registration Statement on Form S-1 (File No. 333-299332) on October 6, 2026. In accordance with Rule 457(b) under the Securities Act, the Company is using $2,375.73 of the previously paid fees to offset the filing fee payable in connection with this Registration Statement.